Sun Pharmaceutical Industries has entered into a definitive agreement to acquire Organon for an enterprise valuation of $11.75 billion in cash, offering $14.00 per outstanding share. Upon completion, the merger is projected to create a combined entity with annual revenues of $12.4 billion, significantly elevating Sun Pharma’s standing in the global pharmaceutical landscape.
Organon, which spun off from Merck & Co (MSD) in 2021, brings a robust portfolio of over 70 products focused on women’s health, general medicines, and biosimilars across 140 countries. By integrating Organon’s assets, Sun Pharma will expand its operational footprint to 150 countries, including 18 markets where annual revenues exceed $100 million each. The transaction is anticipated to nearly double Sun Pharma’s EBITDA and cash flow, while diversifying its manufacturing network with six additional facilities in emerging markets and the European Union.
Dilip Shanghvi, Executive Chairman of Sun Pharma, stated that the acquisition aligns with the company’s vision of “Reaching People and Touching Lives” by creating a more diversified and stronger global platform. This move follows Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics in March 2025, further illustrating the company’s aggressive growth strategy. The deal is expected to close in early 2027, subject to regulatory approvals and the consent of Organon’s stockholders.
Source: https://www.pharmaceutical-technology.com/news/sun-pharma-to-acquire-organon/?cf-view